- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06252441
Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Endoscopic retrograde cholangiopancreatography (ERCP) , a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.
Two definitions were used for diagnosis of PEP. In both definitions, PEP is diagnosed if two of the three criteria are found in the patient .The consensus criteria that was developed by Cotton and Colleagues in 1991 defined PEP as the presence of a new pancreatic-type abdominal pain associated with at least a threefold elevation in pancreatic enzyme concentration occurring 24 hours following the ERCP procedure, with the necessity for a new or extended hospitalization for at least two nights. Severity of pancreatitis is defined based on the number of hospitalized days following ERCP as mild (< 4 days), moderate (4 to 10 days), or severe (>10 days). The revised Atlanta Classification in 2012 lists abdominal pain consistent with acute pancreatitis, amylase or lipase elevation to more than 3 times the upper limit of normal, and abdominal imaging that reveals pancreatic inflammation.
Several potential triggers can contribute to PEP. Mechanical trauma caused by ERCP instrumentation can harm the papilla and pancreatic duct, affecting pancreatic drainage. Thermal injury can occur during biliary or pancreatic sphincterotomy electrosurgical current. Chemical damage can occur when contrast medium is introduced into the pancreatic duct. Hydrostatic damage can occur when injecting contrast media into the pancreatic duct or infusing fluids such as water or saline solution during sphincter manometry. Regardless of the cause, the initial injury sets in motion a chain of events that include premature activation of proteolytic enzymes, autodigestion of pancreatic tissue, and impaired secretion from acinar cells. These events result in pancreatitis clinical symptoms, which have an influence both locally and systemically. Most PEP prevention techniques try to disrupt one or more steps in this cascade.
While the precise mechanism of PEP remains unknown, it is most likely induced by a proinflammatory cascade initiated by pancreatic acinar cell damage, which results in systemic cytokine release. Cytokines play a major role in the pathogenesis of acute pancreatitis as part of the underlying systemic inflammatory response, tissue damage, and organ dysfunction. Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine that promotes the inflammatory response, whereas Interleukin-10 (IL-10) is an immunosuppressive cytokine that inhibits inflammation. These markers can be used in measurement of the degree of systemic inflammation as predictors of the development of PEP.
Phospholipase A2 is essential in this signaling cascade. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that effectively inhibits phospholipase A2 activity. According to this notion, anti-inflammatory drugs such as diclofenac can stop or attenuate the first cascade that leads to clinical PEP.
Previous meta-analyses have suggested that NSAIDs are effective in preventing PEP. The European Society of Gastrointestinal Endoscopy guidelines recommend routine rectal administration of 100 mg of diclofenac or indomethacin immediately before ERCP procedure in all patients without contraindications to NSAIDs administration. Rectal administration route of diclofenac is the most effective in the prevention of PEP. Rectal diclofenac is a cheap, widely available agent with easy administration method and favorable side effect profile.
Oxidative stress and active oxygen species can activate inflammatory cascade and immune responses. N-acetyl cysteine (NAC), an antioxidant drug with anti-inflammatory properties can inhibit oxidative stress as well as inflammatory intermediates, suggesting that it could aid in the prevention of PEP. Despite the failure of intravenous N-acetyl cysteine studies, 2013 pilot research revealed that oral NAC may be useful in reducing PEP. This would be due to the different pharmacokinetics of NAC followed in different studies. In a multicenter global randomized controlled trial investigation, It is reported that oral NAC is more effective than indomethacin in the prevention of PEP.
Although both oral NAC and rectal diclofenac are widely used pharmacological agents, till now no study has evaluated their comparative safety and efficacy in preventing PEP. Hence this study is planned to evaluate and compare their efficacy and safety in preventing PEP.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Mariam Tabana
- Phone Number: 01095153770
- Email: Mariamtabana3@gmail.com
Study Locations
-
-
-
Menofia, Egypt
- Recruiting
- Obstructive Jaundice Clinic in the National Liver Institute, Menoufia University , Shebin Elkoom
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age more than 18 years old.
- Gender: males and females.
- Patients with suitable indications for ERCP due to suspected pancreato-biliary disorders.
- Blood amylase and lipase levels before ERCP are within the normal limits.
Exclusion Criteria:
- Age of less than 18 years old.
- Uncontrolled diabetes mellitus (DM).
- Severe bleeding tendency.
- Impaired renal function (serum creatinine > 2 mg/dL), (creatinine clearance <30 ml/min).
- Patients with severe heart disease.
- Subjects who underwent prior biliary or pancreatic sphincterotomy or dilatation or stenting of either duct.
- Currently pregnant or nursing.
- Admission due to established pancreatitis before ECRP.
- Unwillingness to undergo ERCP.
- Previously documented allergy to NAC or diclofenac or any other NSAIDs.
- History of NSAIDs intake one week before the procedure.
- Recent Active bleeding, ulcer, or asthma.
- Patients with rectal disease (hemorrhoids, fissures, abscesses, and incontinence).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Rectal Diclofenac
This Group will include 23 patients who will receive 100 mg rectal diclofenac before ERCP.
|
100 mg Rectal Diclofenac Before ERCP
|
Active Comparator: Oral N-acetyl cysteine
This Group will include 23 patients who will receive 1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
|
1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The development of pancreatitis after the procedure according to consensus criteria
Time Frame: Before performing ERCP, baseline serum amylase and lipase levels will be measured in all patients. After twenty four ( 24) hours post ERCP procedure, patients' serum amylase and lipase levels will be measured.
|
Briefly in this criteria PEP will be diagnosed if the patient met two of the three following criteria after ERCP: A- New onset or increased abdominal pain consistent with acute pancreatitis B- Pancreatic enzyme elevation to at least three times the upper limit of normal at twenty four (24) hours after the procedure C- Necessity for new or continued hospitalization for at least two nights |
Before performing ERCP, baseline serum amylase and lipase levels will be measured in all patients. After twenty four ( 24) hours post ERCP procedure, patients' serum amylase and lipase levels will be measured.
|
The change in the serum levels of Tumor necrosis factor alpha (TNF-α) and Interleukin-10 (IL-10 )before and after ERCP procedure
Time Frame: Biomarkers will be measured at baseline before the ERCP procedure and twenty four (24 ) hours after the procedure
|
These markers measure the degree of systemic inflammation as predictors of the development of PEP.
|
Biomarkers will be measured at baseline before the ERCP procedure and twenty four (24 ) hours after the procedure
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pancreatic Diseases
- Pancreatitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Protective Agents
- Respiratory System Agents
- Antioxidants
- Antidotes
- Free Radical Scavengers
- Expectorants
- Diclofenac
- Acetylcysteine
- N-monoacetylcystine
Other Study ID Numbers
- Post ERCP Pancreatitis
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post ERCP Pancreatitis
-
University of MichiganUniversity of Kentucky; Case Western Reserve University; Indiana University School...TerminatedPost-ERCP PancreatitisUnited States
-
Hospital San PaoloUnknownPost-ERCP PancreatitisItaly
-
Yonsei UniversityRecruiting
-
Chinese University of Hong KongXijing Hospital; Changhai Hospital; Eastern Hepatobiliary Surgery Hospital; Zhejiang... and other collaboratorsRecruitingPost ERCP PancreatitisChina, Hong Kong, Thailand
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPost-ERCP PancreatitisUnited States, Canada
-
Syed Z. Ali, MDCompleted
-
Yonsei UniversityCompletedPost ERCP PancreatitisKorea, Republic of
-
University Medicine GreifswaldTerminatedPost-ERCP PancreatitisGermany
-
Indiana UniversityMedical University of South Carolina; Beth Israel Deaconess Medical Center; University... and other collaboratorsCompletedPost-ERCP PancreatitisUnited States
-
Grigore T. Popa University of Medicine and PharmacyUnknownPost-ERCP PancreatitisRomania
Clinical Trials on Rectal Diclofenac
-
Binh Dan HospitalCompleted
-
The Hospital of VestfoldVestre Viken Hospital Trust; Ullevaal University Hospital; Oslo University Hospital and other collaboratorsRecruitingQuality of Life | Rectal Cancer | Ileostomy; Complications | Complication,PostoperativeNorway
-
Herlev HospitalUnknown
-
Fujian Medical UniversityZhejiang Cancer Hospital; Sun Yat-sen University; Fudan University; Peking Union... and other collaboratorsActive, not recruiting
-
National Cancer Center, KoreaUnknownRectal CancerKorea, Republic of
-
Dr. Lutfi Kirdar Kartal Training and Research HospitalCompleted
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedColorectal CancerUnited States, Canada
-
University of Southern DenmarkOdense University HospitalRecruitingHirschsprung DiseaseDenmark
-
The University of Hong KongUnknownAdenocarcinoma | Rectal CancerHong Kong
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHIV PreventionUnited States, Malawi, Peru, South Africa, Thailand